New arrangements for migalastat (Galafold®) – information for prescribers

This fact sheet is for current prescribers (treating physicians) with patients requiring treatment for Fabry disease. It explains how a treatment for this condition, migalastat (Galafold®), will be transitioning from the Life Saving Drugs Program to the PBS.

New arrangements for migalastat (Galafold®) – information for prescribers

About this resource

Publication date:
Publication type:
Fact sheet
Language:
English

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.